Life gets busy, and sometimes those basic math skills from school days get a little rusty. Whether you're budgeting, ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

Abbott Laboratories ABT-1.10%decrease; red down pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS 0.04%increase; green up pointing triangle in a deal valued at about ...

We recently published 10 Stocks Beating Wall Street at its Own Game. Exact Sciences Corp. (NASDAQ:EXAS) is one of the best-performing stocks on Wednesday. Exact Sciences climbed to a new two-year high ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. Abbott said Thursday it would buy Exact Sciences, the maker of tests ...

Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...

MADISON (WKOW) -- Abbott announced it will acquire Exact Sciences for an approximate enterprise value of $23 billion. Exact Sciences, a Madison-based company, is known for several products that focus ...

Exact Sciences (EXAS) will likely need to see over $100 a share in a takeover, according to a William Blair analyst, after an earlier report that Abbott Labs (ABT) is in talks to buy the cancer test ...

The Election Commission on Tuesday (November 4, 2025) launched the second phase of the Special Intensive Revision (SIR) of electoral rolls in nine States and three Union Territories, covering around ...

The healthcare diagnostics specialist posted its latest set of quarterly figures. This featured a surprise net profit, among other goodies. Just after market close on Monday, Exact Sciences took the ...

Bloomer announced, "We are raising total full year revenue to between $3.22 billion and $3.235 billion, an increase of $78 million at midpoint. This includes screening revenue between $2.51 billion ...

As Halloween approaches, Exact Sciences is warding off a particularly terrifying occurrence: skipping colorectal cancer screening. A newly launched campaign touts the company’s Cologuard test as a non ...